MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Epithelioid

Epitheliod mesothelioma makes up between 50% and 70% of all diagnosed cases of mesothelioma; it also tends to have the best prognosis.

Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

Clinical Lung Cancer 2018 September 3 [Link] Fodor A, Broggi S, Incerti E, Dell’Oca I, Fiorino C, Samanes Gajate AM, Pasetti M, Cattaneo MG, Passoni P, Gianolli L, Calandrino R, Picchio M,

Comments Off on Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

What’s new in mesothelioma

Pathologica 2018 March [Link] Ascoli V, Murer B, Nottegar A, Luchini C, Carella R, Calabrese F, Lunardi F, Cozzi I, Righi L Abstract Malignant pleural mesothelioma is a neoplasm characterized by a very poor prognosis and medico-legal implications. Diagnosis, prognosis and therapy are often challenging and include several issues. Cytological diagnosis is frequently the first […]

Comments Off on What’s new in mesothelioma

Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

Clinical Lung Cancer 2018 September 3 [Link] Fodor A1, Broggi S2, Incerti E3, Dell’Oca I4, Fiorino C2, Samanes Gajate AM3, Pasetti M4, Cattaneo MG2, Passoni P4, Gianolli L3, Calandrino R2, Picchio M, Di Mu Abstract INTRODUCTION: The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without […]

Comments Off on Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.

Clinical Lung Cancer 2018 August 29 [Link] Verma V, Ahern CA, Berlind CG, Lindsay WD, Shabason J, Sharma S, Culligan MJ, Grover S, Friedberg JS, Simone Abstract INTRODUCTION: For the 3 histologic subtypes of malignant pleural mesothelioma (MPM)-epithelioid, sarcomatoid, and biphasic-the magnitude of benefit with surgical management remains underdefined. MATERIALS AND METHODS: The National Cancer […]

Comments Off on Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.

Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.

Archives of Pathology and Laboratory Medicine 2018 July 30 [Link] Berg KB, Dacic S, Miller C, Cheung S, Churg A Abstract CONTEXT: – The separation of reactive from malignant mesothelial proliferations is often a difficult morphologic problem. There is contradictory information in the literature on whether methylthioadenosine phosphorylase (MTAP) immunohistochemistry can be used for this […]

Comments Off on Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.

Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

Journal of the National Comprehensive Cancer Network 2018 June 16 [Link] Bochtler T, Endris V, Reiling A, Leichsenring J, Schweiger MR, Klein S, Stögbauer F, Goeppert B, Schirmacher P, Krämer A, Stenzinger A Abstract This case report presents a male patient with epithelioid mesothelioma that was initially misdiagnosed as cancer of unknown primary (CUP) and […]

Comments Off on Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

Modern Pathology 2018 May 21 [Link] Chiu K, Lee L, Cheung S, Churg AM Abstract Immunohistochemistry (IHC) is used to help differentiate pleural mesothelioma from pulmonary adenocarcinoma in pleural biopsies and cytology specimens of pleural effusions due to overlapping morphologic features between these two malignancies. The aim of this study is to evaluate IHC glypican-1, […]

Comments Off on Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

Expression of plakophilin 3 in diffuse malignant pleural mesothelioma

Histology and histopathology 2018 May [Link] Mašić S, Brčić L, Krušlin B, Šepac A, Pigac B, Stančić-Rokotov D, Jakopović M, Seiwerth S Abstract Diffuse malignant pleural mesothelioma (DMPM) is the most common primary malignant pleural neoplasm still posing major diagnostic, prognostic and therapeutic challenges. Plakophilins are structural proteins considered to be important for cell stability […]

Comments Off on Expression of plakophilin 3 in diffuse malignant pleural mesothelioma

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

BMC Cancer 2018 April [Link] Giger-Pabst, Demtröder, Falkenstein, Ouaissi, Götze, Rezniczek, Tempfer Abstract BACKGROUND: Patients with recurrent malignant epithelioid mesothelioma (MM) after surgery and standard chemotherapy with cisplatin and pemetrexed have limited treatment options. METHODS: We performed a retrospective cohort study of patients with recurrent MM undergoing Pressurized IntraPeritoneal/Thoracal Aerosol Chemotherapy (PIPAC/PITAC) with doxorubicin 1.5 mg/m2 and cisplatin 7.5 mg/m2. […]

Comments Off on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal

Carcinogenesis 2018 April [Link] Schelch K et.al Abstract Malignant pleural mesothelioma (MPM), an aggressive malignancy affecting pleural surfaces, occurs in three main histological subtypes. The epithelioid and sarcomatoid subtypes are characterized by cuboid and fibroblastoid cells, respectively. The biphasic subtype contains a mixture of both. The sarcomatoid subtype expresses markers of epithelial-mesenchymal transition (EMT) and […]

Comments Off on FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal